Avenue Therapeutics, INC. (ATXI) — SEC Filings

Overview

Avenue Therapeutics, INC. (ATXI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Avenue Therapeutics, Inc. filed an 8-K on December 30, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 1111 Kane Concourse, Suite 301,

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 4 bearish, 28 neutral, 3 mixed. The dominant filing sentiment for Avenue Therapeutics, INC. is neutral.

Filing Type Overview

Avenue Therapeutics, INC. (ATXI) has filed 21 8-K, 2 DEF 14A, 5 10-Q, 2 10-K, 2 SC 13D/A, 1 SC 13G, 2 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

• Avenue Therapeutics Files 8-K on Shareholder Votes — 8-K · Dec 31, 2025 Risk: low
  Avenue Therapeutics, Inc. filed an 8-K on December 30, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's
• ATXI Sets Virtual Annual Meeting to Elect Directors, Ratify Auditor — DEF 14A · Dec 5, 2025 Risk: medium
  Avenue Therapeutics, Inc. (ATXI) is holding its Annual Meeting of Stockholders virtually on December 30, 2025, at 10:00 a.m. Eastern Time. Stockholders will vot
• 8-K Filing — 8-K · Nov 18, 2025
• ATXI Narrows Losses Amid Nasdaq Delisting, AnnJi Deal Termination — 10-Q · Nov 13, 2025 Risk: high
  AVENUE THERAPEUTICS, INC. (ATXI) reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $2.221 million from $1
• 8-K Filing — 8-K · Nov 12, 2025
• Avenue Therapeutics Swings to Profit on AnnJi Deal, Faces Going Concern Doubts — 10-Q · Aug 14, 2025 Risk: high
  Avenue Therapeutics, Inc. reported a net income of $335,000 for the three months ended June 30, 2025, a significant improvement from a net loss of $2.692 millio
• Avenue Therapeutics Files Q1 2025 10-Q with Minimal Financial Activity — 10-Q · May 15, 2025 Risk: medium
  Avenue Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal financial activity for the first quarter of 2025, wi
• Avenue Therapeutics Files 8-K on Agreements and Acquisitions — 8-K · Apr 30, 2025 Risk: medium
  On April 24, 2025, Avenue Therapeutics, Inc. filed an 8-K report detailing several material events. These include entering into and terminating a material defin
• Avenue Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Avenue Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company's primary focus is on the de
• Avenue Therapeutics Faces Delisting Notice — 8-K · Mar 17, 2025 Risk: high
  Avenue Therapeutics, Inc. filed an 8-K on March 17, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
• Avenue Therapeutics Files 8-K — 8-K · Mar 7, 2025 Risk: low
  Avenue Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting other events and financial statements. The company is incorporated in Delaware and its princi
• Avenue Therapeutics Faces Nasdaq Delisting Warning — 8-K · Nov 29, 2024 Risk: high
  Avenue Therapeutics, Inc. announced on November 26, 2024, that it received a notice from The Nasdaq Stock Market LLC regarding its failure to meet the minimum b
• Fortress Biotech Amends Avenue Therapeutics Stake Filing — SC 13D/A · Nov 15, 2024 Risk: medium
  Fortress Biotech, Inc. filed an amendment (No. 5) to its Schedule 13D on November 15, 2024, regarding its holdings in Avenue Therapeutics, Inc. The filing indic
• SC 13G Filing — SC 13G · Nov 14, 2024
• Avenue Therapeutics Q3 2024: Minimal Financial Activity — 10-Q · Nov 14, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed its Q3 2024 10-Q report on November 14, 2024, for the period ending September 30, 2024. The company reported minimal financial a
• Avenue Therapeutics Appoints New CMO, CDO, and Directors — 8-K · Sep 27, 2024 Risk: medium
  Avenue Therapeutics, Inc. announced on September 23, 2024, the appointment of Dr. James R. Scopa as Chief Medical Officer and Dr. Robert L. Smith as Chief Devel
• Avenue Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed its Q2 2024 10-Q report on August 9, 2024, for the period ending June 30, 2024. The company's financial statements show minimal
• Avenue Therapeutics Appoints Dr. James N. Woody as CMO — 8-K · Jun 26, 2024 Risk: medium
  Avenue Therapeutics, Inc. announced on June 24, 2024, the appointment of Dr. James N. Woody as Chief Medical Officer and a member of the Board of Directors. Dr.
• Avenue Therapeutics Files 8-K Report — 8-K · May 23, 2024 Risk: low
  On May 21, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing an "Other Event." The filing does not disclose specific details about the event itself,
• Avenue Therapeutics Files 8-K on Financials — 8-K · May 15, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhi
• Avenue Therapeutics Enters Material Definitive Agreement — 8-K · May 13, 2024 Risk: medium
  Avenue Therapeutics, Inc. announced on May 10, 2024, that it entered into a Material Definitive Agreement. The company, incorporated in Delaware with its princi
• Avenue Therapeutics, Inc. Announces Annual Meeting of Stockholders on June 24, 2024 — DEF 14A · May 6, 2024 Risk: low
  AVENUE THERAPEUTICS, INC. (ATXI) filed a Proxy Statement (DEF 14A) with the SEC on May 6, 2024. Annual Meeting of Stockholders to be held virtually on June 24,
• SC 13G/A Filing — SC 13G/A · May 2, 2024
• Avenue Therapeutics Files 8-K with Key Agreements and Equity Sales — 8-K · May 1, 2024 Risk: medium
  On May 1, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, engaged in
• Avenue Therapeutics Files 8-K: Security Holder Rights & Bylaws Modified — 8-K · Apr 26, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on April 26, 2024, reporting material modifications to security holder rights and other events as of April 25, 2024. The
• Fortress Biotech Amends Avenue Therapeutics Filing — SC 13D/A · Apr 17, 2024 Risk: medium
  Fortress Biotech, Inc. filed an amendment (No. 4) to its Schedule 13D on April 17, 2024, regarding its holdings in Avenue Therapeutics, Inc. The filing indicate
• Avenue Therapeutics Faces Delisting Notice — 8-K · Mar 29, 2024 Risk: high
  Avenue Therapeutics, Inc. filed an 8-K on March 29, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of March 26, 2024. Th
• Avenue Therapeutics Files 8-K on Financials — 8-K · Mar 18, 2024 Risk: low
  On March 18, 2024, Avenue Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statemen
• Avenue Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 18, 2024 Risk: medium
  AVENUE THERAPEUTICS, INC. (ATXI) filed a Annual Report (10-K) with the SEC on March 18, 2024. Avenue Therapeutics, Inc. filed its 2023 Form 10-K on March 18, 20
• Avenue Therapeutics Closes $10M Public Offering — 8-K · Mar 15, 2024 Risk: medium
  On March 11, 2024, Avenue Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised app
• Avenue Therapeutics Files 8-K on Security Holder Vote — 8-K · Mar 8, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on March 8, 2024, reporting that a matter was submitted to a vote of its security holders on March 6, 2024. The filing do
• Avenue Therapeutics Amends Bylaws, Changes Fiscal Year — 8-K · Feb 23, 2024 Risk: medium
  Avenue Therapeutics, Inc. filed an 8-K on February 23, 2024, reporting an event that occurred on February 20, 2024. The filing indicates amendments to its Artic
• Avenue Therapeutics Files 8-K on Shareholder Vote Submission — 8-K · Jan 12, 2024
  Avenue Therapeutics, Inc. filed an 8-K on January 12, 2024, reporting an event that occurred on January 9, 2024, related to the submission of matters to a vote
• Avenue Therapeutics Sells New Equity, Dilution Risk for ATXI Holders — 8-K · Jan 8, 2024
  Avenue Therapeutics, Inc. (ATXI) filed an 8-K on January 8, 2024, reporting a material definitive agreement and unregistered sales of equity securities on Janua
• Sabby Volatility Fund Discloses 661,056 Shares in Avenue Therapeutics — SC 13G/A · Jan 2, 2024
  Sabby Volatility Warrant Master Fund, Ltd. filed an amended SC 13G/A on January 2, 2024, disclosing a shared beneficial ownership of 661,056 shares of Avenue Th

Risk Profile

Risk Assessment: Of ATXI's 28 recent filings, 5 were flagged as high-risk, 18 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Avenue Therapeutics, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $1.404M
• Net Income: -$2.221M
• EPS: -$0.21
• Debt-to-Equity: N/A
• Cash Position: $3.709M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Alexandra MacLean, M.D.
• David Jin
• Lindsay A. Rosenwald, M.D.
• Dr. James R. Scopa
• Dr. Robert L. Smith
• Ms. Jennifer L. Jones
• Mr. David M. Lee
• Dr. James N. Woody

Industry Context

Avenue Therapeutics operates in the biopharmaceutical sector, a highly competitive and research-intensive industry. Success is driven by the ability to develop and gain regulatory approval for novel therapies. The industry is characterized by significant R&D investment, long development cycles, and substantial regulatory hurdles imposed by bodies like the FDA. Companies often face challenges in securing funding and navigating patent landscapes.

Top Tags

corporate-governance (5) · filing (4) · shareholder-vote (3) · 10-Q (3) · material-agreement (3) · financials (3) · pharmaceuticals (3) · Proxy Statement (2) · Director Election (2) · Biotechnology (2)

Key Numbers

• Reverse Stock Split Ratio: 1-for-75 — Effected on April 26, 2024, impacting share count and price
• Class A Preferred Stock Voting Power: 14.0 votes — Per share, significantly higher than common stock
• Annual Meeting Date: December 30, 2025 — Date stockholders will vote on proposals
• Record Date: November 25, 2025 — Date for determining eligible voters for the Annual Meeting
• Number of Directors: 6 — To be elected for a one-year term
• Common Stock Shares Outstanding: 3,183,426 — As of the November 25, 2025 Record Date
• Class A Preferred Stock Shares Outstanding: 250,000 — As of the November 25, 2025 Record Date
• Net loss for nine months ended Sep 30, 2025: $2.221M — Significant reduction from $10.137 million in 2024
• Other revenue for nine months ended Sep 30, 2025: $1.404M — Generated from AnnJi License Agreement termination, compared to $0 in 2024
• Cash and cash equivalents as of Sep 30, 2025: $3.709M — Increased from $2.594 million at Dec 31, 2024
• Accumulated deficit as of Sep 30, 2025: $104.8M — Indicates substantial historical losses
• Common shares outstanding as of Nov 12, 2025: 3,183,558 — Increased from 2,108,670 shares at Dec 31, 2024
• Research and development expenses for nine months ended Sep 30, 2025: $780K — Substantial decrease from $6.080 million in 2024
• Proceeds from ATM sales of common stock, net of issuance costs for nine months ended Sep 30, 2025: $2.094M — Key source of financing activities
• Net loss per common share for three months ended Sep 30, 2025: $0.21 — Significant improvement from $1.92 in 2024

Related Companies

AVTX · AXSM · FBRX · FBIO

Frequently Asked Questions